Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 63Cyclophosphamide 55Radiotherapy 53Bevacizumab 50Doxorubicin 48Ifosfamide 33pazopanib 28fludarabine phosphate 28Etoposide 27Radiation 24Gemcitabine 24pembrolizumab 23Sirolimus 23Sunitinib 22Filgrastim 22Irinotecan 21Whole-Body Irradiation 20Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 20Imatinib Mesylate 20Vincristine 19Magnetic Resonance Spectroscopy 18Sorafenib 16Methotrexate 16Busulfan 16Melphalan 15Carboplatin 15Docetaxel 14Cyclosporine 14temsirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fenofibrate × Sarcoma × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡